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The Association between Ethnicity, 
Stigma, Beliefs about Medicines and 
Adherence in People Living with HIV in a 
Rural Area in Indonesia 
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Background: Indonesia is one of Asia’s countries with the fastest growing rate of human 
immunodeficiency virus (HIV) infections according to the World Health Organization 
(WHO). The prevalence of HIV infections in the province of Papua is 2.4% which is 24 times 
higher than the national rate in Indonesia. This study aimed to investigate the association 
between stigma, beliefs about medicines, sociodemographic characteristics including ethnicity 
and adherence in People living with HIV (PLHIV) in Papua, Indonesia.  
Methods: We conducted a cross-sectional study using questionnaires. We included 
participants from two hospital-outpatient clinics who were on antiretroviral treatment (ART) 
for more than six months, were at least 18 years old, and signed informed consent. 
Participants completed the Medication Adherence Rating Scale (MARS), Beliefs about 
Medicines Questionnaire (BMQ), an HIV stigma scale and questions on demographic 
information. Data on antiretroviral medications were collected from medical records. The 
outcome was self-reported adherence as measured by the MARS using an 80% cut-off score. 
Multivariate logistic regression was used to analyse the data. 
Results: Overall, 331 out of 363 eligible participants were included with a mean age of 33.3 
(± 9.4) years, 61.6% were female, 67.1% were Papuan. A total of 65.9% of participants were 
adherent. Being Papuan decreased the likelihood of adherence (odds ratio (OR) = 0.53; 95% 
confidence interval (CI) = 0.32-0.89). Feeling more distant, a stigma type, also decreased the 
likelihood of adherence (OR = 0.93; 95% CI = 0.88-0.99). 
Conclusions: The ethnicity of being Papuan and taking a distance to others were associated 
with non–adherence. Targeted interventions should be developed to improve adherence in this 
group.  




More than 36 million people who are infected with the human immunodeficiency virus (HIV) 
worldwide require antiretroviral therapy (ART) to reduce mortality and the number of new 
HIV infections [2]. ART is a lifetime medication and adherence to treatment is necessary to 
be effective [3]. Based on a definition by the World Health Organization (WHO), we 
understand adherence to be the extent to which a person’s behavior in taking medication 
corresponds with agreed recommendations from a health care provider [4]. Stigma, family 
responsibilities, and problems with schedule and routine have been recognized as barriers to 
adherence [5].  
 
Stigma is understood as a society’s attitude in disgracing a person or group [6]. Feeling 
stigmatized is very common in people living with HIV (PLHIV). PLHIV can notice the 
stigma resulting in marginalizing behavior towards the PLHIV [7]. It has been shown that 
stigmatized PLHIV were less able to manage their disease [8]. Previous studies have also 
shown that stigma was a significant predictor for a lower level of ART adherence in 
developing and developed countries [9].  
 
Beliefs about Medicines is a concept of cognitive representation of medicines which has been 
introduced by Horne et al [10]. They developed a questionnaire to quantify people’s beliefs of 
the necessity of taking medications versus concerns about adverse effects. In particular, 
having concerns about adverse effects and not being convinced of the necessity of the 
medicines have been found to be associated with non-adherence to ART [11]. Providing 
information and communicating about the complexity of ART and possible adverse effects 
may improve adherence [12].   
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Papua is the easternmost island of Indonesia. In the province of Papua, the majority of the 
population are indigenous Papuans. Ethnic non-Papuans are migrants from other Indonesian 
islands, mostly to seek employment. Indonesia is one of Asia’s countries with the fastest 
growing rate of HIV infections according to the Indonesian Ministry of Health and WHO. The 
prevalence of HIV infections in the province of Papua is 2.4% which is 24 times higher than 
the national rate in Indonesia. Of the 25.000 people living with acquired immune deficiency 
syndrome (AIDS) in Papua [13], less than 6000 PLHIV are on ART [14]. The main mode of 
transmission is through unprotected sex between heterosexuals [13]. In contrast to other areas 
in Indonesia, most of the inhabitants of Papua are Christians.  
 
In 2014, the Indonesian government set the strategic target to have 80% of PLHIV covered by 
ART over 5 years [15]. This may effectively decrease the epidemic. Maintaining adherence to 
ART has been regarded as a major component to achieve this goal. A number of studies have 
investigated the level of ART adherence in Indonesia, but so far, these merely covered urban 
cities in Indonesia with a different sociodemographic and epidemiological context to Papua 
[15],[16]. Only one Indonesian study explored the effect of stigma, again in an urban 
population not using a validated scale to assess stigma [17]. As far as we are aware, beliefs 
about medicines have not been studied systematically in Indonesia. Understanding which 
factors are associated with low medication adherence is the base to develop interventions to 
improve treatment of HIV in rural areas like Papua.  
 
This study aimed to investigate the association between stigma, beliefs about medicines, 
sociodemographic characteristics including ethnicity and adherence in people living with HIV 




Study Design, setting and participants  
This was a cross-sectional study using questionnaires to assess stigma, beliefs about 
medicines and adherence to medication. The participants were recruited from the outpatient 
clinics of one public hospital and one private hospital in Jayapura. These are two out of three 
hospitals providing HIV care in Jayapura. We have selected those two hospitals as they were 
the first ones to provide HIV care by teams of specialists for 10 years. ART is dispensed free 
of charge to patients.  
 
Participants were included if they were at least 18 years old, were on ART for more than six 
months, and signed informed consent. Patients were excluded if more than 50% of data was 
missing. Participants were recruited and informed about the study while they were collecting 
their ART in the hospital. The recruiters, one pharmacist and three nurses who were health 
care professionals from the two HIV study hospitals, explained the aim of the study. They 
also emphasized that all information was kept confidential and that the decision whether to 
participate or not did not affect their treatment in any way. After the participants signed the 
informed consent, an appointment to complete the questionnaires was made for the following 
month as part of their next visit to the hospital.  
 
The sample size was calculated based on the use of a two tailed test with a level of 
significance of 0.05. It was assumed that approximately 77% of the population were adherent 




We have chosen to assess adherence [18], beliefs about medicines [10] and stigma [19] with 
widely used instruments [11],[20],[21].  
 
Adherence  
We used the self–reported Medication Adherence Rating Scale (MARS) [18]. This consists of 
10 questions. This questionnaire assessed the patients’ medication taking behavior in the past 
week. An example of a statement is: “I take my medication only when I am sick”. The 
response is binary, yes/no. A total MARS score is calculated as the sum of all items with a 
maximum score of 10 [18]. A higher total score indicated higher levels of adherence. We 
dichotomized the response into adherence and non-adherence. Sensitivity analyses were 
performed with MARS scores of 7, 8 and 9 as the cut-off (Appendix). The cut-off score of 8 
was the most sensitive and was therefore used for the analysis.  
 
HIV stigma  
The HIV Stigma-Sowell scale consists of 13 questions. These 13 items represent 3 types of 
stigma, namely distancing, blaming and discrimination [22]. A question representing 
distancing is: ”I thought other people were uncomfortable being with me”. A question 
representing blaming is: “I felt I would not get good health care if people knew about my 
illness”. A question representing discrimination is: “I felt compelled to change my residence 
because of my illness”. Answers are scored on a 4 point Likert scale (as: 1= not at all, 2= 
rarely, 3= sometimes and 4= often.) The distancing and blaming scales were assessed with 4 
questions each. The discrimination scale was assessed with 5 questions. The total score ranges 




Beliefs about Medicines Questionnaire (BMQ) 
The BMQ assesses patient’s concepts about medication use in general and patient’s beliefs 
about the medication they use [10]. The BMQ-General part of the questionnaire consists of 
two scales asking about their views on overuse and harm related to medication (four questions 
each). An example of a statement on overuse is: "doctors use too many medicines". An 
example of a statement on harm is: "most medicines are addictive." The BMQ-Specific part 
consists of two scales about the necessity and concerns of patients regarding their medicine (5 
questions each). An example of a statement on necessity is: "my antiretroviral medication 
protects me from becoming worse". An example of a statement on concern is: "I am 
sometimes worried about becoming too dependent on antiretroviral medication”. All 18 
statements were scored on a 5-point Likert scale as 1= strongly disagree, 2= disagree, 3= 
uncertain, 4= agree, 5= strongly agree. The total from every scale of the BMQ was calculated. 
Higher total scores on necessity indicated patients being positive and seeing the advantages 
taking their medication. Higher total scores on concern, overuse, and harm indicated concerns 
about the treatment.  
 
Translation  
Since all instruments were developed and validated in English, we translated the instruments 
forwards into Bahasa Indonesia and backwards into English. The forward translation was 
done by two Indonesian certified translators. Both versions were assessed by DPA as 
proofreader and reviewer with a lot of experience in translating questionnaires. A final, 
reconciled Bahasa version was agreed on. This version was back-translated by an English 
native speaker who had no information about the original versions of the questionnaires. The 
backward translation was modified several times because the target language does not 
recognize verb tenses [1]. Therefore, the final version included words related to time. The 
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final questionnaires were tested in 67 PLHIV who did not participate in the main study. The 
Cronbach’s alpha coefficient to test the internal consistency of the questionnaires was: 0.94 
for the MARS scale, 0.82 for the HIV stigma scale and 0.6 for the BMQ scale, indicating 
good to moderate consistency. Participants indicated they understood the questionnaires.  
 
Data Collection 
At the appointment, participants were handed out the three paper-based questionnaires and 
were also given a questionnaire to collect sociodemographic information (age, gender, marital 
status, whether or not they had children, education, employment, sexual orientation, religion, 
ethnicity, receiving support in medicine-taking from social network, and ART regimen). They 
completed the questionnaires in the waiting area of the hospital. The recruiters were available 
for questions. Information about the age and types of ART were collected from PLHIV’s 
medical records. Data were collected between September and November 2016.  
 
Descriptive statistics 
The sociodemographic variables were analyzed using descriptive statistics. The categorical 
variables were presented as frequencies and percentages. The continuous variables were 
summarized either as mean (standard deviation) or median (interquartile range) depending on 
the nature of the variables. The outcome variable was binary coded as non-adherent and 
adherent. Chi-square test for categorical and independent sample t-test or Mann-Whitney U 
test were used to determine the association between the independent variables and adherence. 
We included the following independent variables in the analyses: age, gender, marital status, 
having children, education, employment, sexual orientation, religion, ethnicity, social support 
in medicine-taking, ART regimen, distancing, blaming and discrimination of the stigma scale 
and necessity, concern, overuse and harm from the BMQ questionnaire.    
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Statistical modelling  
We included all independent variables with a p-value of <0.20 in the descriptive analysis in a 
univariate logistic regression to examine the effect of the independent variables on adherence. 
Then, independent variables with a p-value of <0.20 from the univariate analysis were 
included in the multivariate logistic regression analysis [23]. In the multivariate logistic 
regression analysis, we used a backward elimination procedure to select the final model with 
all independent variables being significant with a p-value of ≤ 0.05. Finally, odds ratios of 
independent variables and their 95% confidence interval were presented.  All analyses were 
done using two-tailed tests at a significance level of 0.05. The statistical analyses were 





We identified 1305 PLHIV starting ART since 2006, successfully contacted and screened 923 
PLHIV of whom 388 were eligible. Finally, 363 participants agreed to sign the informed 
consent and completed the questionnaire (response rate 93%). Thirty-two participants had to 
be excluded. Two participants were excluded because on inspection of their medical records, 
they were below 18 years of age and 30 participants were excluded because of missing 
sociodemographic data. Finally, 331 participants were eligible for data analysis.  
 
Sociodemographic characteristics of participants 
The mean age of participants was 33.3 years (SD= 9.4), 61.6% were female and 67.1% had a 
Papuan ethnicity. Almost all participants were educated (51.7% had a vocational and 21.1% 
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had a high school education). More than half of the participants (58.0%) reported having paid 
employment. The majority (96.4%) were heterosexual, 0.9% were bisexual, and 2.7% were 
gay. The majority reported Protestantism as their religion (74.6%). A fixed dose combination 
(FDC) was used as a single tablet ART by 43.5% of all participants. The majority of 
participants (65.9%) received support in medicine-taking from their social network (Table 1). 
 
Overall, 65.9% of participants reported to be adherent. There were no significant differences 
in gender, marital status, having children, education, employment, sexual orientation, religion, 
and type of regimen between non-adherent and adherent participants. Significant differences 
were observed in age and ethnicity between adherent and non-adherent participants (Table 1). 
Table 2 shows that the most common reasons for being non-adherent were forgetting to take 
ART (72.1%), carelessly taking ART (51.4%) and attitudes towards medication (55.9%).  
 
Multivariate Logistic Regression 
Ethnicity and distancing were significantly associated with adherence. The sociodemographic 
factors (age and employment) and the other independent variables (blaming, concern, and 
harm) were not associated with adherence. Papuans had half the odds of being adherent than 
non-Papuans (OR= 0.53; 95% CI = 0.32-0.89). Feeling distanced also decreased the odds of 
being adherent (OR= 0.93; 95% CI= 0.88-0.99).  
 
DISCUSSION 
This cross-sectional study showed that based on self-reporting, more than one-third of PLHIV 
in Papua, Indonesia were non-adherent. This was lower than in another Indonesian study 
performed in an urban area [17], but results are difficult to compare because of differences in 
methods and instruments used. In line with previous studies, the main reasons for non-
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adherence were forgetfulness, being careless about taking ART, and experiencing adverse 
effects [24]. Ethnicity and experiencing stigma were significantly associated with non-
adherence. 
 
Strength and Limitation  
This was the first study to examine ART adherence in a predominantly heterosexual group of 
PLHIV living in rural Indonesia where data is scarce. We recruited participants when they 
came to pick up their medication, in one region in two hospitals in Indonesia with about 10 
years of experience to care for HIV patients. Our data may not be generalizable to other 
settings and regions. For practical reasons, we used hospital health care professionals to 
recruit patients. We assured patients that participation was voluntary, but some patients may 
have felt obliged to participate. We used questionnaires and achieved the sample size needed. 











(n= 113; 34.1 
%) 
Adherent 
(n= 218; 65.9%) 
    p-value 
Age (mean, SD) 33.3 (9.4) 31.3 (9.4) 34.3 (9.2)  
 18-27 years   43 (38.1) 53 (24.3) 0.019 
 28-37 years  44 (38.9) 91 (41.7) 
 Above 38 years  26 (23.0) 74 (33.9) 
Gender    0.202 
 Female 204 (61.6) 75 (66.4) 129 (59.2) 
 Male 127 (38.4) 38 (33.6) 89 (40.8) 
Marital Status    0.331 
 Not-married 104 (31.4) 31 (27.4) 73 (33.5) 
 Married 200 (60.4) 70 (61.9) 130 (59.6) 
 Divorced/widowed 27 (8.2) 12 (10.6) 15 (6.9) 
Having Children    0.259 
 No 101 (30.5) 30 (26.5) 71 (32.0) 
 Yes 230 (69.5) 83 (73.5) 147 (67.4) 
Education    0.309 
 Elementary school 7 (2.1) 1 (0.9) 6 (2.8) 
 Junior high school 28 (8.5) 7 (6.2) 21 (9.6) 
 High school 70 (21.1) 30 (26.5) 40 (18.3) 
 Vocational 171 (51.7) 57 (50.4) 114 (52.3) 
 University 8 (2.4) 4 (3.5) 4 (1.8) 
 Master 47 (14.2) 14 (12.4) 33 (15.1) 
Employment    0.076 
 Unpaid  139 (42.0) 55 (48.7) 84 (38.5) 
 Paid  192 (58.0) 58 (51.3) 134 (61.5) 
Sexual Orientation    0.335 
 Homosexual 9 (2.7) 1 (0.9) 8 (3.7) 
 Bisexual 3 (0.9) 1 (0.9) 2 (0.9) 
 Heterosexual 319 (96.4) 111 (98.2) 208 (95.4) 
Religion    0.464 
 Protestant 247 (74.6) 88 (77.9) 159 (72.9) 
 Catholic 22 (6.6) 8 (7.1) 14 (6.4) 
 Moslim 62 (18.7) 17 (15.0) 45 (20.6) 
Ethnicity    0.023 
 Non-Papuan 109 (32.9) 28 (24.8) 81 (37.2) 
 Papuan 222 (67.1) 85 (75.2) 137 (62.8) 
Support in medicine-taking from social network    0.280 
 No support 113 (34.1) 43( 38.1) 70 (32.1) 
 Support 218 (65.9) 70 (61.9) 148 (67.9) 
Regimen    0.248 
 Duv-EFV 9 (1.2) 1 (0.9) 8 (3.7) 
 Duv-NEV 29 (2.7) 7 (6.2) 22 (10.1) 
 FDC 144 (43.5) 48 (42.5) 96 (44.0) 
 TDF-3TC-Aluvia 2 (0.6) 1 (0.9) 1 (0.5) 
 TDF-3TC-EFV 59 (17.8) 18 (15.9) 41 (18.8) 
 TDF-3TC-NEV 10 (3.0) 2 (1.8) 8 (3.7) 
 TDF-3TC-Aluvia 3 (0.9) 1 (0.9) 2 (0.9) 
 TDF-FTC-EFV 70 (21.1) 33 (29.2) 37 (17.0) 
 TDF-FTC-NEV 1 (0.3) 0 (0.0) 1 (0.5) 
*SD= Standard Deviation, Duv= Duviral, EFV= Efavirenz, NEV= Nevirapine, FDC= Fixed Dose Combination 
 (TDF+3TC+Efavirenz),TDF= Tenofovir, 3TC= Lamivudine, FTC= Emtricitabine  





Table 2 Medication Adherence Rating Scale (MARS) questionnaire 
 (N= 113 non-adherent participants) 
No The MARS question 
Frequency of responses indicating non-
adherence (%) 
N (%) 
1 Do you ever forget to take your medication? 80 72.1 
2 Are you careless at time about taking your medication? 57 51.4 
3 When you feel better, do you sometimes stop taking your medication? 40 36.0 
4 Sometimes if you feel worse when you take the medication, do you stop taking it? 33 29.7 
5 I take medication only when I am sick 39 35.1 
6 It is unnatural for my mind and body to be controlled by medication 62 55.9 
7 My thoughts are clear on medication 31 27.9 
8 By staying on medication, I can prevent getting sick 33 29.7 
9 I feel weird, like a "zombie" on medication 45 40.5 
10 Medication makes me feel tired and sluggish 43 38.7 
 
 
Table 3 Medians and IQR for the scales used to assess participant's stigma, and  
Beliefs about Medicines (BMQ) comparing non-adherent with adherent 
*IQR Inter Quartile Range  
 
Table 4 Univariate and multivariate analyses on the association of variables with adherence 
Characteristics Univariate  
OR (95% CI) 
p-value  Multivariate  
OR (95% CI) 
p-value  
Age 18-27 years  ref    
28-37 years 1.67 (0.97-2.87) 0.060   
≥ 38 years 2.30 (1.26-4.21) 0.006   
Ethnicity Non-Papuan ref  ref  
Papuan  0.55 (0.33-0.92) 0.024 0.53 (0.32-0.89) 0.017 
Employment Unpaid  ref    
Paid  1.51 (0.96-2.39) 0.077   
Stigma Distancing 0.94 (0.88-1.00) 0.058 0.93 (0.88-0.99) 0.040 
 Blaming 0.93 (0.87-1.00) 0.053   
BMQ Concern 0.95 (0.88-1.01) 0.155   
 Harm 0.94 (0.87-1.01) 0.135   








Adherence      Median 
(IQR) 




4.0-16.0 9.0 (6.0-11.5) 8.0 (4.0-11.0) 0.03 
Blaming Median 
(IQR) 
4.0-16.0 9.0 (6.0-10.5) 7.0 (5.0-10.0) 0.03 
Discrimination 
Median (IQR) 
5.0-20.0 11.0 (8.0-13.5) 10.0 (7.0-13.0) 0.24 




5.0-25.0 18.0 (16.0-20.0) 18.0 (16.0-20.0) 0.62 
Concern Median 
(IQR) 
5.0-25.0 16.0 (14.0-19.0) 16.0 (14.0-18.0) 0.05 
Overuse Median 
(IQR) 
4.0-20.0 12.0 (10.0-14.0) 12.0 (10.0-14.0) 0.48 
Harm Median (IQR) 4.0-20.0 10.0 (8.0-12.0) 9.0 (8.0-11.0) 0.06 
Total BMQ 18.0-90.0 57.0 (52.0-62.0) 55.0 (50.0-60.0)  
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We chose self-reporting to assess adherence. Giving socially desirable answers and recall-bias 
are among the disadvantages of this method [25]. It was outside the scope of this cross-
sectional study to use other methods. The two study hospitals used paper-based medical 
records and there were insufficient data available to calculate adherence using for example 
refill rates. Previous studies suggest that in PLHIV, self-reporting is a suitable method [26]. 
We used the MARS questionnaire that has been developed and validated in schizophrenia 
patients [18] and the use in PLHIV so far was limited [27]. Therefore, a cut-off point for non-
adherence has not been defined previously. In our study, PLHIV had to achieve a score of at 
least 8 out of 10 to be adherent. This is relatively high compared to studies in mental health. 
We chose this cut-off after using sensitivity analysis. This cut-off point is acceptable to be 
used since there is small difference between using 80% and 90% adherence due to virological 
failure [28]. Finally, the available data were insufficient to investigate the association between 
adherence and clinical proxy outcomes such as CD4 counts or viral load. In our setting, those 
outcomes are infrequently assessed because of lack of resources.  
 
Ethnic group was found to be associated with adherence. Being Papuan increased the 
likelihood of being non-adherent. One of the reasons for this could be the difficulties in 
communication between health professionals and PLHIV. Most of the health professionals are 
non-Papuans and therefore do not speak the local language. This is consistent with another 
study which revealed that miscommunication between PLHIV and health providers decreased 
the satisfaction with treatment due to lack of psychological support from health providers 
[29]. It also caused emotional stress and feeling of discomfort due to loss of self-confidence 
[30]. The most recognized complaints of PLHIV about physicians are related to 
communication, not clinical competencies [29]. More work is needed to investigate reasons 
for non-adherence in Papuans. Our findings highlight the importance to investigate the impact 
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of ethnicity on health care in Indonesia which has 300 ethnic groups, in other regions with a 
similar mix of ethnicities. 
 
The second result of this study found that stigma, as assessed by the HIV stigma scale, was a 
significant factor to diminish adherence for PLHIV [9]. Only one of the HIV stigma 
subscales, feeling more distant, was associated with non-adherence whereas blame and 
discrimination were not significant. Experiencing stigma could lead to fear to lose one’s 
companion, and this may result in avoiding treatment hence non-adherence [22]. PLHIV may 
try to isolate themselves from others in an attempt to protect themselves as a way to cope with 
the stress of having an HIV infection [31].  
 
In contrast to other studies, the adherent and the non-adherent group were similar in their 
responses on the BMQ [11]. They perceived a relatively high necessity for ART, but also 
relatively high concerns and worries about overuse and harmful effects. The decision to take 
ART may not be based on the ratio of risk and benefit of ART alone, but other factors such as 
stigma were also important. We also found that the difference between the necessity and 
concern scores were positive for both groups. It means PLHIV were more positive about their 
medication than they feared to experience adverse effects.  
 
Our results have practical implications for health providers. The first step should be to address 
communication barriers between health providers and Papuans. Good communication skills 
may be essential to achieve this. More Papuan social workers from religious institutions may 
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help Papuan PLHIV to solve the miscommunication issues. Overall, more work is needed to 
disentangle the reasons of why Papuans are more likely to be non-adherent. 
 
Distancing, one type of stigma also needs to be addressed. Clinical strategies may be less 
successful without changing behavior associated with stigma in society. Awareness about 
existing stigma may help health professionals to understand patients. Addressing non-
adherence may need a tailored intervention based on PLHIV’s needs. Ultimately, health 
providers are recommended to be active not only to discuss possible adverse effects but also 
to talk about stigma-related issues with PLHIV. Collaboration between health providers and 
social workers may encourage the patient’s family to be active in reducing distance by 
providing more information about HIV. Psychological consultations for PLHIV to learn 
accepting their HIV status should also be available. Such interventions may lead to increased 
self-esteem of stigmatized PLHIV to not isolate themselves and actively visit health centers 
without hesitation.  
 
CONCLUSIONS 
In conclusion, self-reported adherence was relatively low in PLHIV in Papua, Indonesia. 
Ethnicity of being Papuan, and feeling distant from others because of their HIV status were 
associated with non–adherence. Targeted interventions should be developed to improve 




[1] J. Epstein, R. M. Santo, and F. Guillemin, “A review of guidelines for cross-cultural 
adaptation of questionnaires could not bring out a consensus,” J. Clin. Epidemiol., 
2015. 
[2] UNAIDS, “Global AIDS Update,” 2016. 
[3] World Health Organisation, “Consolidated guidelines on the use of antiretroviral drugs 
for treating and preventing HIV infection: recommendations for a public health 
approach,” WHO Guidel., no. June, p. 272, 2013. 
[4] World Health Organization, “Adherence To Long-Term Therapies,” 2003. 
[5] B. L. Genberg, Y. Lee, W. H. Rogers, and I. B. Wilson, “Four types of barriers to 
adherence of antiretroviral therapy are associated with decreased adherence over time,” 
AIDS Behav., vol. 19, no. 1, pp. 85–92, 2015. 
[6] E. Goffman, Stigma: Notes on the Management of Spoiled Identity. Eaglewood Cliffs: 
NJ: Prentice-Hall, 1963. 
[7] O. Bonnington et al., “Changing forms of HIV-related stigma along the HIV care and 
treatment continuum in sub-Saharan Africa: A temporal analysis,” Sex. Transm. Infect., 
vol. 93, pp. 1–6, 2017. 
[8] P. S. Dlamini et al., “HIV stigma and missed medications in HIV-positive people in 
five African countries.,” AIDS Patient Care STDS, vol. 23, no. 5, pp. 377–87, 2009. 
[9] S. Rueda et al., “Examining the associations between HIV-related stigma and health 
outcomes in people living with HIV/AIDS: a series of meta-analyses.,” BMJ Open, vol. 
6, no. 7, p. e011453, 2016. 
[10] R. Horne, J. Weinman, and M. Hankins, “The beliefs about medicines questionnaire: 
The development and evaluation of a new method for assessing the cognitive 
representation of medication,” Psychol. Heal., vol. 14, no. 1, pp. 1–24, 1999. 
[11] R. Horne, S. C. E. Chapman, R. Parham, N. Freemantle, A. Forbes, and V. Cooper, 
“Understanding patients’ adherence-related Beliefs about Medicines prescribed for 
long-term conditions: A meta-analytic review of the Necessity-Concerns Framework,” 
PLoS One, vol. 8, no. 12, 2013. 
[12] S. P. Wasti et al., “Factors influencing adherence to antiretroviral treatment in Asian 
developing countries: A systematic review,” Trop. Med. Int. Heal., vol. 17, no. 1, pp. 
71–81, 2012. 
[13] Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, “Laporan Perkembangan 
HIV/AIDS 7 Penyakit Menular Seksual (PIMS) Triwulan I Tahun 2017,” 2017. 
[14] Dinas Kesehatan Provinsi Papua, “Profil Kesehatan Provinsi Papua Tahun 2016,” 
2017. 
[15] Indonesia National AIDS Commission Indonesia, “Global AIDS Response Progress 
Reporting Indonesia Country Progress Report 2014,” vol. 1, pp. 35–110, 2014. 
[16] Y. Li, R. Hershow, Irwanto, I. Praptoraharjo, M. Setiawan, and J. Levy, “Factors 
Associated with Symptoms of Depression among Injection Drug Users Receiving 
Antiretroviral Treatment in Indonesia.,” J. AIDS Clin. Res., vol. 5, no. 5, p. 303, May 
2014. 
[17] E. R. N. Weaver, M. Pane, T. Wandra, C. Windiyaningsih, Herlina, and G. Samaan, 
“Factors that influence adherence to antiretroviral treatment in an urban population, 
Jakarta, Indonesia,” PLoS One, vol. 9, no. 9, pp. 1–7, 2014. 
[18] K. Thompson, J. Kulkarni, and A. A. Sergejew, “Reliability and validity of a new 
Medication Adherence Rating Scale (MARS) for the psychoses,” Schizophr. Res., vol. 
42, no. 3, pp. 241–247, 2000. 
[19] R. L. Sowell, A. Lowenstein, L. Moneyham, A. Demi, Y. Mizuno, and B. F. Seals, 
“Resources, Stigma, and Patterns of Disclosure in Rural Women with HIV Infection,” 
48 
 
Public Health Nurs., vol. 14, no. 5, pp. 302–312, 1997. 
[20] L. Fialko et al., “A large-scale validation study of the Medication Adherence Rating 
Scale (MARS),” Schizophr. Res., vol. 100, no. 1–3, pp. 53–59, 2008. 
[21] E. W. Farber, A. A. Shahane, J. L. Brown, and P. E. Campos, “Perceived stigma 
reductions following participation in mental health services integrated within 
community-based HIV primary care,” AIDS Care - Psychol. Socio-Medical Asp. 
AIDS/HIV, vol. 26, no. 6, pp. 750–753, 2014. 
[22] C. A. Emlet, “Measuring Stigma in Older and Younger Adults with HIV/AIDS: An 
Analysis of an HIV Stigma Scale and Initial Exploration of Subscales,” Res. Soc. Work 
Pract., vol. 15, no. 4, pp. 291–300, 2005. 
[23] Z. Bursac, C. H. Gauss, D. K. Williams, and D. W. Hosmer, “Purposeful selection of 
variables in logistic regression,” Source Code Biol. Med., vol. 3, pp. 1–8, 2008. 
[24] Z. Shubber et al., “Patient-Reported Barriers to Adherence to Antiretroviral Therapy : 
A Systematic Review and Meta-Analysis,” pp. 1–14, 2016. 
[25] M. Elsievers et al., Drug Utiliation Research: Methods and Application. New York, 
USA: John Willey & Sons, 2016. 
[26] J. M. Simoni, C. R. Pearson, D. W. Pantalone, G. Marks, and N. Crepaz, “Efficacy of 
Interventions in Improving Highly Active Antiretroviral Therapy Adherence and HIV-
1 RNA Viral Load: A Meta-Analytic Review of Randomized Controlled Trials,” J 
Acquir Immune Defic Syndr, vol. 43, pp. s23–s35, 2006. 
[27] T. M. U. Nguyen, A. La Caze, and N. Cottrell, “What are validated self-report 
adherence scales really measuring?: A systematic review,” Br. J. Clin. Pharmacol., vol. 
77, no. 3, pp. 427–445, 2014. 
[28] M. Rosenblum, S. G. Deeks, M. van der Laan, and D. R. Bangsberg, “The risk of 
virologic failure decreases with duration of HIV suppression, at greater than 50% 
adherence to antiretroviral therapy,” PLoS One, vol. 4, no. 9, pp. 1–7, 2009. 
[29] J. F. Ha, D. S. Anat, and N. Longnecker, “Doctor-Patient Communication : A Review,” 
Ochsner J., vol. 10, no. 1, pp. 38–43, 2010. 
[30] E. Scheppers, E. van Dongen, J. Dekker, J. Geertzen, and J. Dekker, “Potential barriers 
to the use of health services among ethnic minorities: a review.,” Fam. Pract., vol. 23, 
no. 3, pp. 325–348, 2006. 
[31] Y. X. Zhang, C. E. Golin, B. Jin, C. B. Emrick, Z. Nan, and M. Q. Li, “Coping 
strategies for HIV-related stigma in Liuzhou, China,” AIDS Behav., vol. 18, no. 






The sensitivity and specificity analysis of cut off for adherence 
Likelihood  
Cut of 70% Non-adherence Adherence Total 
Female 39 165 222 
Male 19 108 109 
Total  58 273 331 
Sensitivity (Papua): 39/58 =0.67 
Specificity (Non-Papua): 108/273=0.39 
Likelihood: 0.67/(1-0.39) = 1.099 
Cut of 80% Non-adherence Adherence Total 
Female 75 129 222 
Male 38 89 109 
Total 113 218 331 
Sensitivity (Papua): 75/113 = 0.66 
Specificity (Non-Papua): 89/218 = 0.41 
Likelihood: 0.66 /(1-0.41) = 1.119 
Cut of 90% Non-adherence Adherence Total 
Female 119 85 222 
Male 70 57 109 
Total 189 142 331 
Sensitivity (Papua): 119/189 = 0.63 
Specificity (Non-Papua): 57/142 = 0.40 
Likelihood: 0.67 /(1-0.40) = 1.117 
 
 
